EPISODE · Oct 31, 2025 · 2 MIN
ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials
from Applied Clinical Trials · host Applied Clinical Trials
In today’s ACT Brief, we spotlight the industry’s push to reduce site technology burden, AstraZeneca’s broad survival gains from the MATTERHORN trial, and Thermo Fisher’s multibillion-dollar acquisition of Clario to advance AI-driven clinical research.
Embed this episode
Ready to play
ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials
0:00
2:43
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Applied Clinical Trials?
This episode is 2 minutes long.
When was this Applied Clinical Trials episode published?
This episode was published on October 31, 2025.
Can I download this Applied Clinical Trials episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!